DK3149019T3 - Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme - Google Patents
Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme Download PDFInfo
- Publication number
- DK3149019T3 DK3149019T3 DK15731260.4T DK15731260T DK3149019T3 DK 3149019 T3 DK3149019 T3 DK 3149019T3 DK 15731260 T DK15731260 T DK 15731260T DK 3149019 T3 DK3149019 T3 DK 3149019T3
- Authority
- DK
- Denmark
- Prior art keywords
- gpbar1
- cholan
- tgr5
- fxr
- prevention
- Prior art date
Links
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 title 2
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 title 2
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 title 1
- QSHQKIURKJITMZ-BRPMRXRMSA-N cholane Chemical class C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC)[C@@]1(C)CC2 QSHQKIURKJITMZ-BRPMRXRMSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITFI20140130 | 2014-05-29 | ||
| PCT/EP2015/061802 WO2015181275A1 (en) | 2014-05-29 | 2015-05-28 | Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3149019T3 true DK3149019T3 (da) | 2020-02-17 |
Family
ID=51454763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15731260.4T DK3149019T3 (da) | 2014-05-29 | 2015-05-28 | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme |
| DK19204247.1T DK3626725T3 (da) | 2014-05-29 | 2015-05-28 | Cholan-derivater til anvendelse ved behandlingen og/eller forebyggelsen af fxr- og tgr5/gpbar1-medierede sygdomme |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19204247.1T DK3626725T3 (da) | 2014-05-29 | 2015-05-28 | Cholan-derivater til anvendelse ved behandlingen og/eller forebyggelsen af fxr- og tgr5/gpbar1-medierede sygdomme |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10407462B2 (da) |
| EP (2) | EP3626725B1 (da) |
| JP (1) | JP6820253B2 (da) |
| KR (1) | KR102491556B1 (da) |
| CN (2) | CN110003301B (da) |
| AU (1) | AU2015265893B2 (da) |
| CA (1) | CA2948585C (da) |
| CY (1) | CY1122631T1 (da) |
| DK (2) | DK3149019T3 (da) |
| EA (1) | EA032820B1 (da) |
| ES (2) | ES2768718T3 (da) |
| FI (1) | FI3626725T3 (da) |
| HR (2) | HRP20230170T1 (da) |
| HU (2) | HUE048351T2 (da) |
| LT (2) | LT3626725T (da) |
| MA (1) | MA39881B1 (da) |
| MX (2) | MX373721B (da) |
| PH (1) | PH12016502327A1 (da) |
| PL (2) | PL3149019T3 (da) |
| PT (2) | PT3626725T (da) |
| RS (2) | RS64050B1 (da) |
| SG (2) | SG10201809362RA (da) |
| SI (2) | SI3626725T1 (da) |
| SM (2) | SMT202000070T1 (da) |
| WO (1) | WO2015181275A1 (da) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| LT3626725T (lt) | 2014-05-29 | 2023-03-10 | Bar Pharmaceuticals S.R.L. | Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai |
| WO2016045480A1 (zh) * | 2014-09-28 | 2016-03-31 | 上海源力生物技术有限公司 | 一种奥贝胆酸的制备方法 |
| CN106999551A (zh) | 2014-11-06 | 2017-08-01 | 英安塔制药有限公司 | 作为fxr/tgr5激动剂的胆汁酸类似物和其使用方法 |
| CN105669811B (zh) * | 2014-11-17 | 2020-09-04 | 正大天晴药业集团股份有限公司 | 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途 |
| WO2016079519A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| KR102527821B1 (ko) | 2014-11-19 | 2023-05-02 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드 |
| KR102526632B1 (ko) | 2014-11-19 | 2023-04-27 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드 |
| MX375863B (es) | 2014-11-19 | 2025-03-07 | Nzp Uk Ltd | Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| CN107231795A (zh) | 2014-11-26 | 2017-10-03 | 英安塔制药有限公司 | 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法 |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3256134A4 (en) | 2015-02-11 | 2018-10-03 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10800807B2 (en) * | 2015-06-19 | 2020-10-13 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| US11072631B2 (en) * | 2015-09-24 | 2021-07-27 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation bile acid derivatives |
| WO2017147137A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
| WO2017147159A1 (en) * | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| WO2017147174A1 (en) * | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| WO2017156024A1 (en) | 2016-03-11 | 2017-09-14 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
| CN105859817A (zh) * | 2016-05-09 | 2016-08-17 | 成都宇西医药技术有限公司 | 一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法 |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| WO2017207648A1 (en) | 2016-05-31 | 2017-12-07 | Bionice, S.L.U | Process and intermediates for the preparation of obeticholic acid and derivatives thereof |
| WO2017208165A1 (en) * | 2016-06-01 | 2017-12-07 | Dr. Reddy’S Laboratories Limited | Process for preparation of obeticholic acid |
| SI3730487T1 (sl) | 2016-06-13 | 2022-08-31 | Gilead Sciences, Inc. | Azetidinski derivati kot modulatorji FXR (NR1H4) |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| IT201600068742A1 (it) * | 2016-07-01 | 2018-01-01 | Bar Pharmaceuticals Soc A Responsabilita Limitata | Derivati dell'acido iodesossicolico e loro uso |
| EP3548038B1 (en) | 2016-11-29 | 2022-04-13 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| WO2018152171A1 (en) | 2017-02-14 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr agonists and methods of use thereof |
| KR102743630B1 (ko) | 2017-03-28 | 2024-12-18 | 길리애드 사이언시즈, 인코포레이티드 | 간 질환을 치료하기 위한 치료 조합물 |
| BR112019020780A2 (pt) * | 2017-04-07 | 2020-04-28 | Enanta Pharm Inc | processo para preparação de derivados de ácido biliar de carbamato de sulfonila |
| CN109021054B (zh) * | 2017-06-09 | 2021-04-09 | 博瑞生物医药（苏州）股份有限公司 | 一种fxr激动剂 |
| CN109021056B (zh) * | 2017-06-09 | 2021-03-09 | 博瑞生物医药（苏州）股份有限公司 | 法尼酯x受体激动剂 |
| CN109021055B (zh) * | 2017-06-09 | 2021-04-09 | 博瑞生物医药（苏州）股份有限公司 | Fxr激动剂 |
| WO2019020067A1 (zh) * | 2017-07-26 | 2019-01-31 | 正大天晴药业集团股份有限公司 | 甾体类衍生物fxr激动剂的制备方法 |
| EP3705487B1 (en) * | 2017-11-02 | 2022-10-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for preparing cholic acid compound |
| FI3911647T3 (fi) | 2019-01-15 | 2024-03-01 | Gilead Sciences Inc | Isoksatsoliyhdiste fxr-agonistina ja sitä käsittäviä lääkekoostumuksia |
| CA3129949C (en) | 2019-02-19 | 2024-04-30 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| CA3156985A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| CN112824425B (zh) * | 2019-11-21 | 2023-10-03 | 成都西岭源药业有限公司 | 一种6-位烯基取代胆酸化合物及其制备方法和应用 |
| JP7745559B2 (ja) | 2020-02-28 | 2025-09-29 | キャリーオペ，インク． | Ｇｐｒ４０アゴニスト |
| IT202000008515A1 (it) * | 2020-04-21 | 2021-10-21 | Bar Pharmaceuticals Soc A Responsabilita Limitata | Metodo per la sintesi di un derivato del colano |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| IT202200011705A1 (it) * | 2022-06-01 | 2023-12-01 | Prec Bio Therapeutics S R L | Derivati del colesterolo e loro usi |
| US20250375459A1 (en) * | 2022-07-01 | 2025-12-11 | Intercept Pharmaceuticals, Inc. | Methods for ameliorating cognitive impairment using bile acid derivatives |
| IT202200018669A1 (it) | 2022-09-13 | 2024-03-13 | Bar Pharmaceuticals Soc A Responsabilita Limitata | Combinazioni farmaceutiche comprendenti derivati del colano e loro usi |
| EP4611888A1 (en) * | 2022-10-31 | 2025-09-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
| WO2024195903A1 (ko) * | 2023-03-21 | 2024-09-26 | 경희대학교 산학협력단 | 신규한 콜린산 유도체 및 이의 용도 |
| GB202314563D0 (en) * | 2023-09-22 | 2023-11-08 | Nzp Uk Ltd | Compounds |
| WO2025202883A1 (en) * | 2024-03-25 | 2025-10-02 | Bar Pharmaceuticals Societa' A Responsabilita' Limitata | Cholane derivatives for the treatment and the prevention of fxr and tgr5gp-bar1 receptors mediated diseases |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2326850T3 (es) * | 1998-12-23 | 2009-10-20 | Glaxo Group Limited | Ensayos para ligandos de receptores nucleares. |
| AU2002308295B2 (en) * | 2001-03-12 | 2007-08-23 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
| EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| DK1734970T3 (da) * | 2004-03-12 | 2015-02-16 | Intercept Pharmaceuticals Inc | Behandling af fibrose under anvendelse af FXR-ligander |
| ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| PT2040713E (pt) * | 2006-06-27 | 2014-10-13 | Intercept Pharmaceuticals Inc | Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr |
| US8940719B2 (en) * | 2006-07-03 | 2015-01-27 | Academia Sinica | Lithocholic acid analogues that inhibit sialyltransferase |
| FR2908310B1 (fr) * | 2006-11-14 | 2009-07-10 | Phytodia | Produits agonistes de tgr5 et leurs applications |
| EA017714B1 (ru) * | 2007-01-19 | 2013-02-28 | Интерсепт Фармасьютикалз, Инк. | Модуляторы tgr5 и способы их применения |
| EP1947108A1 (en) * | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| EA020310B1 (ru) | 2008-07-30 | 2014-10-30 | Интерсепт Фармасьютикалз, Инк. | Модуляторы рецептора tgr5 и их применение |
| ES2592452T3 (es) * | 2008-11-19 | 2016-11-30 | Intercept Pharmaceuticals, Inc. | Moduladores de TGR5 y métodos de uso de los mismos |
| EP2376519B1 (en) * | 2008-11-19 | 2013-11-13 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and method of use thereof |
| EP2575821B1 (en) * | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| WO2012047495A2 (en) * | 2010-09-27 | 2012-04-12 | Kythera Biopharmaceuticals, Inc. | Methods for preparing synthetic bile acids and compositions comprising the same |
| US20130034536A1 (en) * | 2011-08-04 | 2013-02-07 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis |
| EP3336097B1 (en) | 2012-06-19 | 2020-08-19 | Intercept Pharmaceuticals, Inc. | Preparation of the non-crystalline form of obeticholic acid |
| SMT201700602T1 (it) * | 2012-10-26 | 2018-03-08 | Intercept Pharmaceuticals Inc | Processo per la preparazione di derivati dell’acido biliare |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
| CN103143021A (zh) * | 2013-03-21 | 2013-06-12 | 中国药科大学 | PPARα-UGT通路抑制剂在治疗炎性肠疾病中的应用 |
| PT3360881T (pt) * | 2013-05-14 | 2021-02-19 | Intercept Pharmaceuticals Inc | Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e conjugados de aminoácidos dos mesmos como moduladores do recetor farnesoide x |
| US9540415B2 (en) * | 2013-08-01 | 2017-01-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the farnesoid X receptor and uses in medicine |
| WO2015183794A1 (en) * | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
| LT3626725T (lt) * | 2014-05-29 | 2023-03-10 | Bar Pharmaceuticals S.R.L. | Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai |
| US20170233431A1 (en) * | 2016-02-17 | 2017-08-17 | City Of Hope | Bile acid derivatives and methods for synthesis and use |
-
2015
- 2015-05-28 LT LTEP19204247.1T patent/LT3626725T/lt unknown
- 2015-05-28 HU HUE15731260A patent/HUE048351T2/hu unknown
- 2015-05-28 AU AU2015265893A patent/AU2015265893B2/en active Active
- 2015-05-28 SG SG10201809362RA patent/SG10201809362RA/en unknown
- 2015-05-28 SI SI201531924T patent/SI3626725T1/sl unknown
- 2015-05-28 KR KR1020167034084A patent/KR102491556B1/ko active Active
- 2015-05-28 EP EP19204247.1A patent/EP3626725B1/en active Active
- 2015-05-28 PL PL15731260T patent/PL3149019T3/pl unknown
- 2015-05-28 JP JP2017514960A patent/JP6820253B2/ja active Active
- 2015-05-28 CN CN201910107511.6A patent/CN110003301B/zh active Active
- 2015-05-28 EP EP15731260.4A patent/EP3149019B1/en active Active
- 2015-05-28 CN CN201580028528.2A patent/CN106661079B/zh active Active
- 2015-05-28 LT LTEP15731260.4T patent/LT3149019T/lt unknown
- 2015-05-28 RS RS20230132A patent/RS64050B1/sr unknown
- 2015-05-28 PT PT192042471T patent/PT3626725T/pt unknown
- 2015-05-28 PL PL19204247.1T patent/PL3626725T3/pl unknown
- 2015-05-28 HR HRP20230170TT patent/HRP20230170T1/hr unknown
- 2015-05-28 ES ES15731260T patent/ES2768718T3/es active Active
- 2015-05-28 ES ES19204247T patent/ES2938874T3/es active Active
- 2015-05-28 WO PCT/EP2015/061802 patent/WO2015181275A1/en not_active Ceased
- 2015-05-28 DK DK15731260.4T patent/DK3149019T3/da active
- 2015-05-28 SG SG11201609403UA patent/SG11201609403UA/en unknown
- 2015-05-28 MX MX2016015724A patent/MX373721B/es active IP Right Grant
- 2015-05-28 SM SM20200070T patent/SMT202000070T1/it unknown
- 2015-05-28 RS RS20200163A patent/RS59910B1/sr unknown
- 2015-05-28 PT PT157312604T patent/PT3149019T/pt unknown
- 2015-05-28 SM SM20230057T patent/SMT202300057T1/it unknown
- 2015-05-28 DK DK19204247.1T patent/DK3626725T3/da active
- 2015-05-28 HR HRP20200225TT patent/HRP20200225T1/hr unknown
- 2015-05-28 FI FIEP19204247.1T patent/FI3626725T3/fi active
- 2015-05-28 EA EA201692316A patent/EA032820B1/ru unknown
- 2015-05-28 MA MA39881A patent/MA39881B1/fr unknown
- 2015-05-28 MX MX2020004024A patent/MX388957B/es unknown
- 2015-05-28 SI SI201531091T patent/SI3149019T1/sl unknown
- 2015-05-28 CA CA2948585A patent/CA2948585C/en active Active
- 2015-05-28 US US15/314,771 patent/US10407462B2/en active Active
- 2015-05-28 HU HUE19204247A patent/HUE061506T2/hu unknown
-
2016
- 2016-11-22 PH PH12016502327A patent/PH12016502327A1/en unknown
-
2019
- 2019-08-01 US US16/529,571 patent/US11117926B2/en active Active
-
2020
- 2020-02-12 CY CY20201100131T patent/CY1122631T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3206686T3 (da) | Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker | |
| DK3227262T3 (da) | Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling | |
| DK3402888T3 (da) | Middel og fremgangsmåder til behandling af hbv | |
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3185957T3 (da) | Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3395353T3 (da) | Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade | |
| DK3183010T3 (da) | Anordning og tilhørende fremgangsmåde til behandling af medicinsk affald | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3362449T3 (da) | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose | |
| BR112016022976A2 (pt) | Métodos para o tratamento de hcv | |
| DK3157531T3 (da) | Fremgangsmåder og sammensætninger til stimulering af det intestinale enteroendokrinesystem til behandling af sygdomme eller tilstande relateret hertil | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose | |
| DK3191103T3 (da) | Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner | |
| DK3149049T3 (da) | Il-22 til anvendelse til behandling af stofskiftesygdomme | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3261642T3 (da) | Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner |